23.05.2019 MeVis Medical Solutions AG  DE000A0LBFE4

DGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for the first half of fiscal 2018/2019


 

DGAP-News: MeVis Medical Solutions AG / Key word(s): Half Year Results
MeVis Medical Solutions AG: MeVis publishes figures for the first half of fiscal 2018/2019

23.05.2019 / 16:00
The issuer is solely responsible for the content of this announcement.


Stable revenues and costs

  • Revenues at EUR 4.0 million approximately 2 % above previous year's level
  • EBIT of EUR 3.6 million in the first half year (compared to EUR 3.1 million in the previous year)
  • EBIT margin stable at 44 % (previous year 38 %)
  • Profit after tax of EUR 4.4 million (compared to EUR 2.4 million in the previous year)

Bremen, May 23, 2019 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces the results for the second quarter and first half of fiscal year 2018/2019 (reporting period October 1, 2018 to March 31, 2019).

Revenues in the second quarter of fiscal year 2018/2019 amounted to EUR 4,033 k, about 2 % above the previous year's level (EUR 3,950 k). License business declined by 23 % in the second quarter to EUR 1,104k (prev. year: EUR 1,438 k), and the maintenance business remained relatively constant at EUR 1,721 k (prev. year: EUR 1,712 k). The service business increased from EUR 799 k in the previous year's period to EUR 1,208 k. Revenues in the first half-year thus amounted to EUR 8,244 k (prev. year: EUR 8,233 k) and were allocated to the segments Digital Mammography with EUR 4,622 k (prev. year: EUR 5,710 k), Development Services with EUR 1,991 k (prev. year: EUR 767 k) and Other Operating Activities with EUR 1,631 k (prev. year: EUR 1,756 k). With a share of 56 % (prev. year: 69 %), the Digital Mammography segment continued to be the main source of revenues.

EBIT (Earnings before financial result and taxes) amounted to EUR 3,647 k in the reporting period (prev. year: EUR 3,136 k). At 44 %, the EBIT margin improved compared with a previous year's value of 38 %.

The financial result improved significantly in the reporting period to EUR 711 k (prev. year: EUR -768 k). The change compared with the previous year is due to the development of the balance of income and expenses from exchange rate differences of EUR 820 k (prev. year: EUR -1,280 k) and the deterioration in the result of the 51 % share in MeVis BreastCare GmbH & Co. KG of EUR -184 k (prev. year: EUR 444 k), which is recognized at equity.

Net profit after taxes therefore amounted to EUR 4,358 k (prev. year: EUR 2,366 k), corresponding with undiluted earnings per share of EUR 2.39 (prev. year: EUR 1.30).

The interim report for the third quarter of fiscal year 2018/2019 will be published on August 29, 2019.


Contact:
Kirchhoff, Marcus / CEO



23.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: [email protected]
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 815311

 
End of News DGAP News Service

815311  23.05.2019 

fncls.ssp?fn=show_t_gif&application_id=815311&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 18,54 16,76 18,07 17,13 16,21 18,76 17,34
EBITDA1,2 9,18 7,60 8,25 5,97 4,77 7,99 3,99
EBITDA-Marge3 49,51 45,35 45,66 34,85 29,43 42,59
EBIT1,4 7,96 6,69 8,00 5,81 4,64 7,90 3,89
EBIT-Marge5 42,93 39,92 44,27 33,92 28,62 42,11 22,43
Jahresüberschuss1 5,62 7,17 8,07 5,70 4,55 7,79 4,92
Netto-Marge6 30,31 42,78 44,66 33,27 28,07 41,52 28,37
Cashflow1,7 7,32 5,52 6,55 2,89 9,13 4,86 5,85
Ergebnis je Aktie8 3,09 3,94 4,43 3,13 2,50 4,28 2,70
Dividende8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
MeVis Med. Solutions
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LBFE 25,400 Halten 46,23
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,58 10,27 1,03 7,74
KBV KCV KUV EV/EBITDA
2,59 7,90 2,67 10,79
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,95 0,95 3,74 19.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 27.05.2024 - 29.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,82% -5,52% 0,79% -23,95%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MeVis Medical Solutions AG  ISIN: DE000A0LBFE4 können Sie bei EQS abrufen


Medtech , A0LBFE , M3V , XETR:M3V